BeOne Medicines MANGROVE Trial Results For BRUKINSAThe MANGROVE study demonstrated that BRUKINSA plus rituximab reduced the risk of progression or death by 43% compared to the standard treatment of bendamustine plus rituximab.This pivotal trial marks a significant advancement in chemotherapy-free treatment options for patients with mantle cell lymphoma, with full results expected to be presented at an upcoming medical meeting.The oncology-focused company said that MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions.Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for the second half of 2026.ONC Technical Analysis: Trend, RSI And Key LevelsBeOne Medicines stock is currently trading at $286.41, which is about 1.9% below its 50-day simple moving average (SMA) of $290.57. The stock is also 5.7% below its 100-day SMA of $302.51, indicating a bearish trend in the medium term.The Relative Strength Index (RSI) is at 53.15, suggesting that the stock is in a neutral position, neither overbought nor oversold. This indicates that there could be potential for further movement in either direction, depending on upcoming market conditions and investor sentiment.